Corrigendum to P-207: A multi-center, phase 1b study to assess the safety, Pharmacokinetics and efficacy of subcutaneous Isatuximab plus Pomalidomide and Dexamethasone, in patients with Relapsed/Refractory Multiple Myeloma [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) Pages S152-S153]

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 6, p. 424, doi. 10.1016/j.clml.2022.03.009

By:

• Moreau, Philippe;
• Parmar, Gurdeep;
• Prince, Miles;
• Ocio, Enrique M.;
• Karanes, Chatchada;
• Madan, Sumit;
• Oriol, Albert;
• Bories, Pierre;
• Delforgel, Michel;
• Gabrail, Nashat;
• Semiondi, Dorothee;
• Jia, Nan;
• Macé, Sandrine;
• Suzan, Florence;
• van de Velde, Helgi;
• Quach, Hang

Publication type:

Article